These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11888030)

  • 1. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
    Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP
    Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S; Pavelka K; Cline GA; Hosterman MA; Barton IP; Cohen SB; Bensen WG
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
    Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
    Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
    Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
    Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.